ChipMOS Technologies Q3 Net Earnings Decline, Revenue Increases-March 2024-www.financetom.com

ChipMOS Technologies Q3 Net Earnings Decline, Revenue Increases

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

ChipMOS Technologies Q3 Net Earnings Decline, Revenue Increases

Nov 5, 2024 2:26 AM

04:46 AM EST, 11/05/2024 (MT Newswires) -- ChipMOS Technologies ( IMOS ) reported Q3 net earnings Tuesday of 0.41 New Taiwan dollars ($0.01) per basic share, down from NT$0.80 a year earlier.

Three analysts surveyed by Capital IQ expected NT$0.76.

Revenue for the quarter ended Sept. 30 was NT$6.07 billion, up from NT$5.58 billion a year earlier.

Four analysts surveyed by Capital IQ expected NT$6.41 billion.

Previous page： Google says tech infrastructure investment in Singapore reaches $5 bln Next page： AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google says tech infrastructure investment in Singapore reaches $5 bln

Jun 3, 2024

Singapore June 3 - Alphabet's Google said on Monday the completion of its data centre and cloud facilities expansion in Singapore meant it had invested $5 billion in its technical infrastructure in the Southeast Asian nation. The company said its data centres in Singapore employ over 500 people and are used to power services such as Google Search and Maps....

AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients

Jun 3, 2024

04:32 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 trial showed its Imfinzi drug reducing the risk of death by 27% versus placebo in patients with limited-stage small-cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy. The company said the drug, also known as durvalumab, is the first and only immunotherapy...

Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise

Jun 3, 2024

04:27 AM EDT, 06/03/2024 (MT Newswires) -- Gilead Sciences ( GILD ) and Arcus Biosciences ( RCUS ) said on Sunday data from Cohort B of Phase 1b/2 study evaluating its experimental combination therapy of etrumadenant, zimberelimab, and chemotherapy could meaningfully improve clinical outcomes for people with metastatic colorectal cancer who have failed at least two prior treatments. The companies...

Maersk faces significant port congestion in Asia, Mediterranean

Jun 3, 2024

OSLO, June 3 (Reuters) - Maersk faces significant terminal congestion in Mediterranean and Asian ports, causing substantial delays in its vessel schedule, the Danish shipping group said in a statement on Monday. As a result of the congestion, the company will skip two westbound sailings from China and South Korea that had been planned to depart in early July, it...